

Inflammatory mediators in the pathogenesis of periodontitis

Tülay Yucel-Lindberg* and Tove Båge

Periodontitis is a chronic inflammatory condition of the periodontium involving interactions between bacterial products, numerous cell populations and inflammatory mediators. It is generally accepted that periodontitis is initiated by complex and diverse microbial biofilms which form on the teeth, i.e. dental plaque. Substances released from this biofilm such as lipopolysaccharides, antigens and other virulence factors, gain access to the gingival tissue and initiate an inflammatory and immune response, leading to the activation of host defence cells. As a result of cellular activation, inflammatory mediators, including cytokines, chemokines, arachidonic acid metabolites and proteolytic enzymes collectively contribute to tissue destruction and bone resorption. This review summarises recent studies on the pathogenesis of periodontitis, with the main focus on inflammatory mediators and their role in periodontal disease.

The inflammatory response is vital for our survival and occurs throughout many processes in our bodies. Among other things, inflammation is a necessary component for our defence against pathogens and in wound healing. In response to an injury or infection, acute inflammation occurs immediately and is usually short-lived. However, when inflammation remains unresolved, it evolves into chronic inflammation because host immune and inflammatory responses are insufficient to remove or clear the microbial challenge which initiates and perpetuates the disease. In chronic inflammation, tissue destruction and healing usually occur at the same time, but the balance is delicate and can tilt towards destruction. In the oral cavity, bacteria are constantly present and can trigger an inflammatory response to induce gingivitis, a reversible periodontal disease affecting gingival tissue. The balance between the resident

microbiota and the host might be disrupted by either compromised host responses (e.g. poorly controlled diabetes mellitus) or an increase in the microbial challenge (e.g. cessation of oral hygiene procedures). In disease-susceptible individuals, gingivitis may progress into periodontitis, the irreversible stage of periodontal disease, with the presence of both gingival inflammation and clinical attachment loss.

Periodontal disease is common and around 5–15% of the population suffers from severe periodontitis (Refs 1, 2, 3, 4). The definition of periodontitis is based on a number of clinical criteria, including bleeding on probing, periodontal pocket depth and clinical attachment loss (Ref. 5). The specific use of these criteria however, varies substantially between different studies and cohorts, indicating a lack of consensus in the epidemiologic case definition of periodontitis and in measurement

Department of Dental Medicine, Division of Periodontology, Karolinska Institutet, SE-141 04 Huddinge, Sweden.

*Corresponding author: Tülay Yucel-Lindberg, Department of Dental Medicine, Division of Periodontology, Karolinska Institutet, SE-141 04 Huddinge, Sweden. E-mail: tulay.lindberg@ki.se

Accession information: doi:10.1017/erm.2013.8; Vol. 15; e7; August 2013

© Cambridge University Press 2013. The online version of this article is published within an Open Access environment subject to the conditions of the Creative Commons Attribution-NonCommercial-ShareAlike licence <<http://creativecommons.org/licenses/by-nc-sa/3.0/>>. The written permission of Cambridge University Press must be obtained for commercial re-use.

methods for the disease (Refs 5, 6). The primary hallmark of periodontitis, the destruction of periodontal tissue, is widely accepted to be a result of the host immune inflammatory response caused by periodontal microorganisms (Refs 7, 8).

The host response has traditionally been considered to be mediated mainly by B and T lymphocytes, neutrophils and monocytes/macrophages. These are triggered to produce inflammatory mediators, including cytokines, chemokines, arachidonic acid metabolites and proteolytic enzymes, which collectively contribute to tissue degradation and bone resorption by activation of several distinct host degradative pathways (Refs 9, 10). In recent years, resident cells in gingival connective tissue have also been revealed as important contributors to the inflammatory response and the increased levels of various inflammatory mediators (Refs 11, 12, 13). The role of the host response in periodontal disease is complex, and with regard to cell infiltration, polymorphonuclear leukocytes (PMNs), which are first to arrive, are the dominant cell type within the junctional epithelium and gingival crevice. Regarding inflammatory mediators, studies have previously demonstrated that cytokines, chemokines and prostaglandins, which are all within the scope of this review, play a critical role in periodontal tissue breakdown (Refs 14, 15, 16, 17). One important effector mechanism of the inflammatory mediators present in periodontal tissue is stimulation of the formation of osteoclasts, multinucleated cells believed to be the major cell type responsible for bone resorption (Refs 18, 19).

Pathogenesis of periodontitis

Besides dental caries, periodontal disease is one of the most prevalent diseases in the world and includes the major conditions gingivitis and periodontitis. The milder, reversible form of the disease, gingivitis, comprises inflammation of the gingival tissue. In disease-susceptible individuals, gingivitis may progress to periodontitis, which is a chronic inflammatory state of the gingiva causing destruction of connective tissue as well as of alveolar bone resulting in reduced support for the teeth and ultimately tooth loss (Fig. 1) (Refs 20, 21, 22).

The pathogenesis of periodontitis has been gradually elucidated during the later half of the




Figure 1. Characteristics of periodontitis. Healthy periodontal tissue (left) and periodontitis (right). Periodontitis is characterised by degradation of the soft connective tissue and alveolar bone supporting the tooth, ultimately resulting in tooth loss.

20th century. In the 1960s and 1970s, research on humans and animals showed that bacteria play a critical role in initiating gingivitis and periodontitis (Refs 23, 24, 25). Leading up to the 1980s, there were further advances within the field and the pivotal role of the host inflammatory response in disease progression began to emerge (Refs 26, 27, 28). The importance of hereditary factors was subsequently demonstrated in several studies, including those comparing monozygotic and dizygotic twins (Refs 29, 30). Systemic conditions and environmental factors such as smoking were also shown to greatly affect the disease onset and progress (Refs 7, 31, 32). For over a decade now, the concept of periodontitis has been considered to be a complex interaction between the microbial challenge and the host response, which alters connective tissue and




Figure 2. Schematic overview of the pathogenesis of periodontitis. The pathogenesis of periodontitis comprises of a complex interaction between the microbial challenge and the host response, resulting in an altered bone metabolism. Bacterial components of the biofilm, such as LPS, antigens and toxins initiate a host immune and inflammatory response which activates host defence cells including PMNs and triggers an antibody response directed towards reducing the magnitude of the microbial challenge. Activation of defence cells results in the production of inflammatory mediators such as cytokines, chemokines, prostaglandins and proteolytic enzymes (e.g. MMPs) that alter connective tissue and bone metabolism. If host immune and inflammatory responses are insufficient to remove or clear the microbial challenge, a chronic inflammatory response develops leading to periodontal inflammation (redness, swelling and bleeding) and periodontal damage (clinical attachment loss). LPS, Lipopolysaccharide; MMPs, matrix metalloproteinases; and PMNs, polymorphonuclear leukocytes.

bone metabolism and causes periodontal damage, i.e. clinical attachment loss (Fig. 2) (Ref. 7). Each of these parts is complex in its own right, but the focus of this review will be on the host response and the intricate network of inflammatory mediators that orchestrate it.

Host response

Bacterial components, such as lipopolysaccharides (LPS), peptidoglycans, lipoteichoic acids, proteases and toxins, which instigate the inflammatory reaction, can be found in the biofilm on tooth surfaces (Refs 31, 32). The host response to the bacterial challenge includes the action and stimulation of various inflammatory cell types as well as of resident cells of the tissue, as schematically illustrated in (Fig. 3) (Refs 7, 33, 34, 35, 36, 37). The “red complex” comprising the pathogens *Tannerella forsythia*, *Porphyromonas gingivalis* and *Treponema denticola*, has been demonstrated in the biofilms at sites expressing progressing periodontitis (Refs 38, 39). Antigens and products, such as LPS and peptidoglycans, released by bacteria are recognised by toll-like receptors (TLRs) on the surface of host cells, which initiates an inflammatory response (Ref. 40).

Through a cascade of events, mast cells are stimulated to release vasoactive amines and preformed tumour necrosis factor α (TNF α), which increases vascular permeability and the expression of adhesion molecules such as intercellular adhesion molecule-1 (ICAM-1) and P-selectin on endothelial cell surfaces (Refs 32, 34). This process recruits PMNs into the tissue, where they release lysosomal enzymes, which contribute to tissue degradation (Ref. 34). In response, lymphocytes and macrophages further invade the tissue. At this point, 60–70% of the collagen in the gingival connective tissue is degraded at the site of the lesion, but the bone is still intact (Refs 26, 34). At this stage, it is still possible for gingival tissues to repair and remodel without permanent damage. However, in some individuals, owing to innate susceptibility and/or environmental factors, the inflammation fails to resolve, with subsequent connective tissue breakdown and irreversible bone loss (Refs 34, 41, 42). In this scenario, macrophages form pre-osteoclasts which, after maturing into osteoclasts, are capable of degrading alveolar bone (Ref. 18).

Without active resolution of inflammation, the bacterial antigens eventually encounter antigen-




Figure 3. Inflammatory mediators in the pathogenesis of periodontitis (See next page for legend.)

presenting cells such as dendritic cells, macrophages and B cells. When naïve CD4 T helper cells (Th0) interact with antigen-presenting cells, naïve T cells differentiate into various subsets of cells including Th1, Th2, Th17 and regulatory T cells (Tregs), depending on the cytokines which they produce. Th1 cells drive the cell-mediated immune response and produce interferon- γ (IFN- γ), transforming growth factor- β (TGF- β), interleukin-2 (IL-2) and TNF α in the presence of IL-12. Th2 cells mediate the humoral immune response and produce the cytokines IL-4, IL-5, IL-6, IL-10, IL-13 and TGF- β in the presence of IL-4. The additional two CD4 T cells, Th17 and Tregs play a critical role in autoimmunity and in the maintenance of immune homeostasis. The Th17 subset of cells secrete IL-17, IL-23, IL-22, IL-6 and TNF α in the presence of TGF- β , IL-1 β and IL-6 whereas Tregs arise in the presence of TGF- β and secrete the immunosuppressive cytokines IL-10 and TGF- β . Notably, IL-17 stimulates the production of various inflammatory mediators including TNF α , prostaglandin E₂ (PGE₂), IL-6 and IL-1 β , mediating bone resorption via osteoclasts activation. Defective regulation of the immune system by Treg cells, thought to mediate the resolution of inflammation, contributes to the pathogenesis of several autoimmune diseases, such as rheumatoid arthritis (RA), multiple sclerosis and colitis (Refs 34, 35, 36, 37, 43, 44). Tregs and Th17 cells have been demonstrated to occur in periodontal tissue with an increased expression of Foxp3 and IL-17, characteristic markers of Tregs and Th17 cells, in periodontitis

suggesting an important role for these cells in the immunoregulation of periodontitis (Refs 34, 37, 45). Numerous studies, however, indicate a plasticity between Treg and Th17 cell subsets which coexist in the same tissues, including periodontitis lesions (Ref. 45). Further studies are thus required to elucidate the role of the balance between the T cell subsets, Treg/Th17 and Th1/Th2, and their cross-talk in the pathogenesis of periodontitis.

Besides invading inflammatory cells, which produce inflammatory mediators and drive the inflammatory process, resident gingival cells may also affect the progression and persistence of periodontitis. Blood vessels, consisting of endothelial cells and smooth muscle cells, are the first to come in contact with invading inflammatory cells. In gingival connective tissue, the most ubiquitous resident cells are gingival fibroblasts. By producing inflammatory mediators, such as cytokines, chemokines, proteolytic enzymes and prostaglandins, these cells participate in the inflammatory response and contribute to disease persistence (Refs 31, 46, 47, 48, 49, 50, 51). Periodontal ligament fibroblasts, located between the tooth and the alveolar bone, are also involved in the inflammatory reaction and produce inflammatory mediators such as prostaglandins, proteolytic enzymes and factors which affect bone resorption (Refs 52, 53, 54). Throughout each step of the inflammatory process, proinflammatory mediators are released which affect various cell types and propel the inflammatory cascade. These mediators, which are the focus of this

Figure 3. Inflammatory mediators in the pathogenesis of periodontitis. (Legend; see previous page for figure.) The host response in periodontitis is a complex interplay between numerous cell types and inflammatory mediators, some of which are illustrated here. (1) In innate immunity, components of the pathogens present in the oral biofilm, such as LPS, stimulate mast cells to release vasoactive amines and preformed TNF α and cause a release of inflammatory mediators in resident cells of the gingival tissue. (2) Through the action of the released mediators, inflammatory cells are recruited into the tissue. (3) PMN leucocytes release lysosomal enzymes, and in response to the milieu of inflammatory mediators, MMP levels increase. MMPs and lysosomal enzymes contribute to degradation of the gingival tissue. (4) Lymphocytes and macrophages invade the tissue. Antigen-presenting cells activate Th0 cells. T-cell-produced cytokines can increase or inhibit the production of inflammatory mediators. (5) Cytokines and PGE₂ affect RANKL and OPG expression, resulting in the formation and activation of osteoclasts capable of alveolar bone degradation. IFN- γ , interferon- γ ; IL, interleukin; LPS, Lipopolysaccharide; MMP, matrix metalloproteinase; OPG, osteoprotegerin; PAMPs, pathogen-associated molecular patterns; PGE₂, prostaglandin E₂; PMN, polymorphonuclear leukocytes; RANK, receptor activator of nuclear factor- κ B; RANKL, receptor activator of nuclear factor- κ B ligand; TGF- β , transforming growth factor β ; TLRs, toll-like receptors; TNF α , tumour necrosis factor α ; and Treg, regulatory T cell.

review, include proinflammatory cytokines, chemokines and arachidonic acid metabolites such as prostaglandins.

Cytokines and chemokines

Numerous cytokines and chemokines have been detected in the gingival crevicular fluid (GCF), exudates collected at the gingival margin, and in gingival tissue from patients with periodontitis. Table 1 summarises the changes in cytokine and chemokine levels determined in GCF and gingival tissue during periodontitis and the effect of periodontal treatment on these levels.

Several proinflammatory cytokines including IL-1, IL-6, IL-12, IL-17, IL-18, IL-21, TNF α and IFN- γ have been demonstrated to be involved in the pathogenesis of periodontitis. The prominent cytokines IL-1 and IL-6, for example, are produced in the B-cell/plasma cell response which characterises the progression of periodontitis (Ref. 34). IL-6 is produced by epithelial cells, lymphocytes, monocytes and fibroblasts in response to bacterial LPS, IL-1 and TNF α and has been shown to stimulate the formation of osteoclasts *in vitro* (Refs 32, 84). Enhanced levels of IL-6 have been demonstrated in the GCF of patients with periodontitis, compared with healthy controls, and higher expression of IL-6 was reported in diseased gingival tissues when compared with healthy tissue in periodontitis patients (Refs 71, 85). Similarly, increased circulating systemic levels of IL-6 decreased after nonsurgical periodontal therapy resulting in clinical improvement of the periodontal status (Ref. 86).

The inflammatory cytokines IL-1 and TNF α play a prominent role in the pathogenesis of periodontitis (Ref. 87). As mentioned above, TNF α is involved at an early stage in the inflammatory cascade, as it is released from mast cells in response to bacterial challenge. In the clinical context, TNF α and IL-1 β have been found in increased concentrations in GCF and gingival tissue of periodontitis sites (Refs 79, 88, 89), and levels are reported to decrease after treatment of periodontal disease (Refs 55, 59). The pivotal role of these cytokines in periodontitis is further supported by reports that attachment loss is reduced in periodontitis patients with RA after anti-TNF treatment and that the administration of recombinant TNF α or IL-1 to the gingiva exacerbates experimental periodontitis in rats (Refs 90, 91, 92). In

addition, soluble receptors of IL-1 and TNF have been shown to greatly inhibit the progress of periodontitis in a primate model (Refs 14, 93). At the cellular level, these two cytokines are involved in the induction of several other inflammatory mediators, such as IL-6, IL-8, matrix metalloproteinases (MMPs) and PGE₂ (Refs 20, 32, 94, 95, 96). The cellular mechanisms underlying the direct involvement of TNF α and IL-1 β in inducing bone resorption are covered later in this review. The cytokines TNF α and IL-1 are themselves synthesised by many cell types in the periodontal tissue: monocytes/macrophages, PMN cells, fibroblasts, epithelial cells, endothelial cells and osteoblasts (Ref. 87). These two cytokines seem to occupy a spider-in-the-web position among mediators of the inflammatory cascade in periodontitis. However, there is substantial interplay between numerous cytokines involved in the inflammatory response, and studies are ongoing to identify additional key players for future treatment and management of inflammatory diseases.

Chemokines are cytokines involved in inducing chemotaxis in responsive cells. In periodontitis, the chemokines IL-8, monocyte chemoattractant protein-1 (MCP-1) and macrophage inflammatory protein-1 α (MIP1 α) attract neutrophils and other leucocytes to the inflammation site. IL-8 is secreted by various cells, including monocytes, lymphocytes, epithelial cells, endothelial cells and fibroblasts, in response to IL-1, TNF α and LPS (Refs 20, 97). High levels of IL-8 expression have been shown to be localised to sites with high concentrations of PMN cells in gingival tissue from patients with aggressive periodontitis (Ref. 98). In addition, enhanced levels of IL-8 were demonstrated in the GCF collected from periodontitis sites compared with healthy control sites and IL-8 levels decreased after periodontal therapy (Ref. 72). The chemokine MCP-1 is produced by endothelial cells, epithelial cells and fibroblasts in response to bacterial components such as LPS or inflammatory mediators (Refs 32, 99). The involvement of MCP-1, and also MIP1 α and RANTES (regulated on activation, normal T cell expressed and secreted), in periodontitis is supported by studies demonstrating increased levels of the chemokines in gingival biopsies and/or GCF of patients with periodontitis, as well as decreased levels of chemokines in the

Table 1. Cytokine levels in the gingival crevicular fluid and in gingival tissue

Cytokine	Role of cytokine	Change in periodontitis	Change after treatment
IL-1 α	Proinflammatory	Increased in GCF (Refs 55, 56, 57), with correlation to clinical parameters (Ref. 58)	Decreased in GCF (Refs 55, 56)
IL-1 β	Proinflammatory	Increased in GCF (Refs 55, 56, 57, 59, 60, 61), with correlation to clinical parameters (Refs 58, 62, 63, 64) Increased protein expression (Refs 65, 66)	Decreased total amount (Refs 55, 56, 59) Increased concentration in GCF (Ref. 67)
IL-4	Anti-inflammatory	Decreased total amount in GCF (Ref. 60) Increased total amount in GCF (Refs 57, 64) Decreased concentration in GCF (Ref. 64) Increased concentration in GCF (Ref. 68)	Increased in GCF (Refs 68, 69, 70)
IL-6	Proinflammatory	Increased in GCF (Refs 57, 61, 71) with correlation to clinical parameters (Ref. 63)	Decreased in GCF (Ref. 56)
IL-8	Chemokine	Increased in GCF (Refs 57, 59, 61) with correlation to clinical parameters (62, 63)	Decreased in GCF (Refs 56, 59, 72)
IL-10	Anti-inflammatory	Increased total amount in GCF (Refs 59, 64), correlated to clinical parameters (Ref. 63) Increased concentration in GCF (Ref. 59) Decreased concentration in GCF (Ref. 64)	Decreased in GCF (Ref. 59)
IL-12 (p40)	Proinflammatory	Increased in GCF (Ref. 57) Increased protein expression (Ref. 73)	Decreased in GCF (Ref. 56)
IL-17	Proinflammatory	Increased mRNA expression (Ref. 74) Increased in GCF (Ref. 75)	Decreased in GCF (Refs 70, 75)
IL-18	Proinflammatory	Increased in GCF with correlation to clinical parameters (Ref. 76)	Decreased in GCF (Ref. 76)
IL-21	Proinflammatory	Increased in GCF (Ref. 77)	Decreased in GCF (Ref. 70)
IFN- γ	Proinflammatory	Increased in GCF (Refs 57, 78) Increased mRNA expression (Ref. 78)	Decreased in GCF (Refs 56, 69) No changes in GCF (Ref. 70)
TNF α	Proinflammatory	Increased in GCF with correlation to clinical parameters (Refs 62, 63, 79) Increased protein expression (Ref. 80)	Increased concentration in GCF (Ref. 67) No change in GCF (Ref. 81) Decreased in GCF (Ref. 82)

(continued on next page)

Table 1. Cytokine levels in the gingival crevicular fluid and in gingival tissue (continued)

Cytokine	Role of cytokine	Change in periodontitis	Change after treatment
MCP-1	Chemokine	Increased in GCF (Ref. 57) with correlation to clinical parameters (Refs 76, 79) Increased mRNA expression (Ref. 83)	Decreased in GCF (Refs 56, 76)
MIP1 α	Chemokine	Increased in GCF (Ref. 57)	Decreased in GCF (Ref. 56)
RANTES	Chemokine	Increased in GCF (Refs 57, 59) Increased mRNA expression (Ref. 83)	Decreased in GCF (Refs 56, 59)

GCF volumes increase with increasing size of periodontal pockets, which is a hallmark of periodontitis. Owing to the large variations between healthy and diseased GCF volumes, changes in total amount and concentration of the inflammatory mediators may differ. Whether the data are a total amount or a concentration is noted in relevant cases

GCF, gingival crevicular fluid; IL, interleukin; IFN- γ , interferon- γ ; TNF α , tumour necrosis factor α ; MCP-1, monocyte chemoattractant protein-1; MIP1 α , macrophage inflammatory protein-1 α ; RANTES, regulated on activation, normal T cell expressed and secreted.

GCF after periodontal treatment (Refs 56, 57, 59, 76, 79, 83).

Various cytokine gene polymorphisms have been reported to be associated with periodontitis (Refs 100, 101). Gene polymorphisms in the genes for IL-1, TNF α , IL-6 and IL-10 as well as combined genotypes of TNF α and lymphotoxin alpha have been reported in patients with periodontitis (Refs 102, 103, 104, 105, 106). These reports support the view of periodontitis as a disease that is largely dependent on the manner of the inflammatory response to components of the oral biofilm. The nature of the inflammatory response is collectively influenced by individual genetic differences in the host, specific components of the oral microbiome and past history of periodontal infection.

Arachidonic acid metabolites – prostaglandins

A range of arachidonic acid metabolites are produced in the gingival tissues. These eicosanoids include prostanoids and leukotrienes, which are produced from arachidonic acid through distinct enzymatic systems. Leukotrienes, known to play an important role in asthma and allergy, are also involved in bone remodelling (Refs 107, 108). Their involvement in periodontitis remains to be investigated, although some data indicate raised levels of the mediators in the disease (Refs 109, 110). Leukotriene B₄ (LTB₄) in particular has been

implicated in RA, which is highly similar to periodontitis in that it is a chronic inflammatory condition which affects bone remodelling. A possible role for LTB₄ has been suggested in the progression of periodontal disease because of the findings that the substantial increase in GCF LTB₄ concentrations, which are associated with the severity of periodontal disease, decreased following periodontal treatment (Ref. 109). Some leukotrienes also have anti-inflammatory effects, and one such leukotriene investigated in relation to periodontal disease is Resolvin E₁ (RvE₁). This anti-inflammatory eicosanoid has been reported to down-regulate inflammation-induced bone loss in experimental periodontitis (Ref. 111) and inhibit osteoclast growth and bone resorption by interfering with osteoclast differentiation (Ref. 112). It was also recently reported that RvE₁ restored impaired phagocytic activity in macrophages from the blood of patients with aggressive periodontitis (Ref. 113) and inhibited LTB₄-induced production of the antimicrobial peptide LL-37 from PMNs, thus terminating the LL-37/LTB₄ proinflammatory circuit (Ref. 114).

Prostaglandins are a group of potent arachidonic acid-derived inflammatory mediators with the capacity to induce a wide variety of biological responses (Ref. 115). They influence many biological processes, including vasodilatation, vascular permeability, oedema, pain and fever, and the mediator also play an immunoregulatory role in neutrophil and

monocyte chemotaxis (Ref. 116). Prostaglandins, synthesised by virtually all mammalian cells, are local hormones, acting at or near the site of their synthesis. They function in both an autocrine and a paracrine fashion and modulate the responses of other hormones, which have profound effects on many cellular processes (Refs 115, 117, 118, 119). Among prostaglandins, PGE₂ is the most prominent in the pathogenesis of periodontitis (Refs 108, 120). PGE₂ is produced by immune cells, fibroblasts and other resident gingival cells and has a wide range of biological effects on the cells of the diseased gingiva (Refs 46, 120). The actions of PGE₂ include the stimulation of inflammatory mediators and MMPs, as well as osteoclast formation via receptor activator of nuclear factor- κ B ligand (RANKL) (Refs 120, 121, 122). The effect of PGE₂ on a specific cell type depends on the prostaglandin receptors, EP₁ through EP₄. The receptors most relevant to the pathogenesis of periodontitis are EP₂ and EP₄, which are reported to activate adenylate cyclase and protein kinase A signalling (Ref. 123). In rodent models, these two receptors have been shown to be involved in bone resorption in response to PGE₂ (Refs 124, 125).

Several clinical alterations observed in periodontal disease can be associated with PGE₂, especially when IL-1 and TNF α are present in the gingival tissue. PGE₂ is detected at significantly higher levels in human inflamed gingival tissue and especially from periodontal sites exhibiting recent attachment loss (Refs 126, 127, 128). Higher levels of PGE₂ are also found in the GCF of patients with periodontitis compared with levels found in GCF of healthy individuals (Refs 129, 130, 131). Accordingly, increasing levels of PGE₂ in crevicular fluid have been suggested to serve as a predictor of periodontal attachment loss (Ref. 132). Furthermore, polymorphisms within the cyclooxygenase-2 (COX-2) gene as well as the methylation levels within the COX-2 promoter, which affect COX-2 mRNA expression, have been repeatedly implicated in periodontitis (Refs 133, 134). Altogether, over-production of PGE₂ is suggested to have a significant role in the pathobiology of periodontitis (Refs 127, 129, 135).

Inflammatory mediators and tissue destruction

Maintenance of the extracellular matrix is important for normal development and function

of gingival tissue. Proteolytic MMP enzymes and their endogenous inhibitors, tissue inhibitors of metalloproteinases (TIMPs), are involved in the homeostasis of the extracellular matrix in healthy tissue, but they are also key players in the process of tissue destruction in inflammatory diseases. Besides modifying the extracellular matrix, MMPs are also involved in regulating the activities of cytokines and cytokine receptors. In periodontitis, both host- and bacteria-derived proteolytic enzymes contribute to the degradation of the extracellular matrix of the connective tissue. Numerous host proteolytic enzymes such as MMPs, elastase, mast cell tryptase, dipeptidyl-peptidase, plasminogen activators and the lysosomal cysteine proteinases, cathepsins and protease 3 have been detected in the GCF of patients with periodontitis (Refs 136, 137). Increased expressions of MMPs (gelatinase and collagenase) are associated with pathological conditions including RA and periodontitis.

MMP expression and activity are in general low in noninflamed periodontium but increase to pathologically high levels in inflamed gingiva, where increased levels of inflammatory mediators upregulate MMP expression (Ref. 138). Studies also suggest, however, that MMP-8 and -9 have the capacity to exert anti-inflammatory effects by processing anti-inflammatory cytokines and chemokines (Refs 138, 139, 140, 141). Among the MMPs, levels of MMP-8 and -13 have been correlated with the severity of periodontal disease (Refs 10, 138, 142). In addition, MMP-8, TIMP-1 and carboxyterminal telopeptide of type I collagen (ICTP) and especially their ratios and combinations are potential candidates in the detection of advanced periodontitis through salivary diagnostics (Ref. 143). Recently, it was reported that MMP-3 and TIMP-1 mRNA expression were significantly higher in diseased tissues than control tissues and that polymorphisms of MMP-3 and TIMP-1 are associated with chronic periodontitis (Ref. 144). In addition, MMP-1, MMP-3 and MMP-9 polymorphisms were newly demonstrated to be associated with susceptibility to periodontitis in a Chinese population (Ref. 145).

In *in vitro* studies, the inflammatory mediators IL-1 β , TNF α and bacterial LPS upregulate MMP-1, -3, -8 and -9 expression in gingival fibroblasts (Refs 146, 147, 148, 149). Moreover, the periodontal pathogen *Porphyromonas gingivalis*, in

the presence of cigarette smoke condensate, increases collagen degradation and protein levels of MMP-1, -2, -3 and -14 in gingival fibroblasts (Ref. 150). The cytokine IL-1 β stimulates MMP-2 expression via a PGE₂-dependent mechanism in human chondrocytes (Ref. 151). The close interactions between PGE₂ and the MMPs are further emphasised by the key role of PGE₂ in the regulation of MMP-9 expression in macrophages and in the induction of MMP-3 and MMP-13 in chondrocytes via the PGE₂-regulatory enzyme microsomal prostaglandin E synthase-1 (mPGES-1) (Refs 152, 153). Moreover, PGE₂ stimulates MMP-1 production in human gingival fibroblasts via activation of mitogen-activated protein kinases (MAPKs)/activator protein-1 (AP-1) and nuclear factor- κ B (NF- κ B) (Ref. 154) and in mouse osteoblasts via the cAMP-PKA signalling pathway (Ref. 155).

The TIMPs that control MMP activity and thereby act as regulators of MMP-mediated extracellular matrix breakdown play an important role in tissue remodelling and the pathology of periodontal tissue destruction (Ref. 156). TIMP levels are generally higher in healthy periodontal tissue compared with inflamed periodontal tissue, resulting in an excess of MMP levels over TIMP-1 levels (Ref. 156). In GCF samples, levels of TIMP-1 and -2 are decreased whereas the levels of MMP-1, -2, -3 and -9 are increased in periodontitis-affected patients compared with healthy controls (Ref. 157). MMP inhibition via nonantimicrobial tetracyclines such as doxycycline has been suggested as a potential treatment of chronic inflammatory diseases, including periodontitis. It has been shown that treatment with doxycycline, as an adjunct to periodontal treatment, suppressed collagenase activity in the periodontal pocket of patients with periodontitis (Ref. 158), which suggests significant therapeutic potential for nonantimicrobial tetracyclines in treatment of periodontal disease.

Inflammatory mediators and bone resorption

Bone resorption is a well-regulated process which depends on the differentiation of monocytes to osteoclasts capable of bone resorption. Although bone formation and bone resorption are processes which occur continuously in healthy alveolar bone, in periodontitis, the normal balance is shifted towards resorption through

mechanisms including increased osteoclast activation. Cytokines such as IL-1 β , TNF α , IL-6, macrophage colony-stimulating factor (M-CSF), IL-17 and PGE₂ are among the more important proinflammatory mediators reported to stimulate osteoclast activation (Refs 159, 160). The TNF family cytokine RANKL induces the differentiation of osteoclasts in the presence of M-CSF (Ref. 161) and activates TRAF6 (member of TNF receptor associated factor), c-Fos and calcium signalling pathways, which are indispensable for the induction and activation of nuclear factor of activated T cells (NFAT) c1, a key transcription factor for osteoclastogenesis. Recently, it was also demonstrated that Wnt5a, a member of the highly conserved Wnt protein family, upregulates RANK expression in osteoclast precursors enhancing RANKL-induced osteoclastogenesis proposing Wnt5a as a new co-stimulatory cytokine for osteoclastogenesis (Ref. 162). In the context of periodontitis, elevated levels of RANKL and reduced levels of osteoprotegerin (OPG) were detected in the GCF samples of patients with periodontitis and the RANKL/OPG ratio was suggested as a possible biomarker test for detection of bone destruction (Ref. 163). OPG acts as a decoy receptor for RANKL and inhibiting OPG expression enables RANKL to interact with its receptor RANK on other cells. RANKL then binds to RANK on osteoclast lineage cells to drive differentiation to osteoclasts (Fig. 3) (Refs 18, 123). The ratio of the GCF levels of RANKL and OPG was higher in patients with periodontitis compared with healthy subjects, suggesting that increased RANKL and/or decreased OPG contribute to osteoclastic bone destruction in periodontal disease (Ref. 164).

IL-1 and TNF stimulate bone resorption by increasing osteoclast formation (Ref. 165) and furthermore, IL-1 also mediates the osteoclastogenic effect of TNF by enhancing expression of RANKL and differentiation of osteoclast precursors (Ref. 166). Inflammatory cytokines such as IL-1 β induce RANKL and/or OPG expression in several cell types, including osteoblasts, gingival fibroblasts and periodontal ligament fibroblasts (Refs 54, 167). Similarly, IL-6, produced and secreted by various cells including fibroblasts and osteoblasts, induces osteoclast formation and stimulates bone resorption and IL-6 receptor blockade/antagonist strongly reduces osteoclast formation in inflamed joints and bone erosion in vivo

(Ref. 168). The importance of RANKL and its downstream transcription factor NF- κ B in inflammation-induced bone resorption has been shown in collagen-induced arthritis in mice, where blocking of NF- κ B reduced disease severity by decreasing TNF α and IL-1 β levels, abrogating joint swelling and reducing destruction of bone and cartilage (Ref. 169).

The major pathway by which the inflammatory mediator PGE₂ stimulates bone resorption is generally considered to be via the up-regulation of RANKL expression and the inhibition of OPG expression in osteoblastic cells (Ref. 123). In osteoclastogenesis, the stimulatory effect of oral pathogen sonicates has been demonstrated to be mainly mediated through the PGE₂/RANKL pathway in primary mouse osteoblasts co-cultured with bone marrow cells (Ref. 170). It has also been reported that RANKL-stimulated osteoclastogenesis can be enhanced by PGE₂ and LPS through direct effects on the haematopoietic cell lineage (Ref. 121). PGE₂ has been shown both to inhibit and stimulate OPG expression (Refs 54, 171), a contradiction which may be the result of differing incubation times, as has been suggested for the effect of PGE₂ on osteoclast formation (Ref. 123).

Modulation of host response

Periodontitis is a complex disease in which the host immune inflammatory response caused by the bacterial challenge results in connective tissue destruction and bone resorption. During disease activity, numerous inflammatory cells and resident cells in the periodontium express and/or stimulate inflammatory mediators including PGE₂, cytokines, chemokines, MMPs and proteins of signal transduction pathways collectively contributing to the destruction of soft and hard tissue. Traditional periodontal therapy has focused on decreasing the microbial challenge by mechanically disrupting and removing bacterial biofilms that form on tooth surfaces and adjacent soft tissue. A growing number of studies, however, have indicated strong potential for adjunctive host-modulating drugs as new therapeutic strategies in the management of periodontal disease (Refs 172, 173).

Inhibition of inflammatory mediator PGE₂

The biosynthesis of PGE₂ involves three different groups of enzymes acting sequentially. The first group of enzymes, phospholipase A₂ (PLA₂),

converts membrane lipids to AA (Refs 174, 175). The second group of isoenzymes, COX-1 and COX-2, convert AA to prostaglandin H₂ (PGH₂) (Ref. 176). Multiple enzymes then metabolise the intermediate PGH₂ to diverse prostaglandins, including PGE₂, PGF₂, PGD₂ and PGI₂ (Refs 176, 177). The third group of isoenzymes, prostaglandin E synthase (PGE synthase), which is the terminal enzyme in the synthesis of PGE₂, catalyses the conversion of COX-derived PGH₂ to PGE₂ (Refs 178, 179).

As Nobel Laureate John R. Vane first suggested in 1971 (Ref. 180), the COX enzymes are the primary targets for nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin. NSAIDs inhibit the first step of the reaction, the formation of PGG₂. Specific COX-2 inhibitors have been developed to achieve inhibition of inflammation-induced PGE₂ production without the detrimental inhibition of baseline, COX-1-derived prostaglandin production was thought to account for the gastrointestinal side-effects of traditional NSAIDs (Ref. 181). Treatment strategies with nonselective NSAIDs and selective COX-2 inhibitors have suggested a potential adjuvant role for COX-inhibitors in periodontal therapy (Ref. 182). Evidence from animal experiments and clinical trials demonstrates that both NSAIDs and selective COX-2 inhibitors are generally responsible for stabilisation of periodontal conditions by reducing the rate of alveolar bone resorption (Ref. 183). Recently, it was also reported, in a small sample size, that "low-dose" aspirin may reduce the risk of periodontal attachment loss (Ref. 184). In contrast, adjunctive treatment with oral administration of meloxicam does not seem to improve clinical parameters or GCF levels of PGE₂ and IL-1 β (Ref. 185). In experimental periodontitis of rats, the selective COX-2 inhibitor celecoxib and prophylactic omega-3 fatty acid, alone and in combination, inhibit gingival tissue MMP-8 expression (Ref. 186).

However, COX-2-specific drugs have several side-effects, including cardiovascular problems (Ref. 187), and one of the COX-2-specific pharmaceutical inhibitors, Vioxx, was withdrawn from the market because of these side-effects. Owing to the side-effects experienced during COX enzyme inhibition, particular attention has been given to the downstream enzymes of the PGE₂ cascade synthesis. Recently, several

different groups of compounds that inhibit mPGES-1 activity have been described (Refs 188, 189). One of the most promising groups of inhibitors are the disubstituted phenanthrene imidazoles, which were found to be orally active in a guinea pig model (Ref. 190). The indole 5-lipoxygenase-activating protein inhibitor MK-886 and its derivatives have been shown to inhibit mPGES-1 in enzyme assays (Ref. 191). Furthermore, natural products such as curcumin (Ref. 192) (from the spice turmeric) and epigallocatechin-3-gallate (Ref. 193) (from green tea) have been shown to affect mPGES-1 in vitro. Several mPGES-1 inhibitors are being studied in animal models, but none are as yet available for use in humans (Refs 194, 195, 196, 197). In experimental periodontitis in rats, the mPGES-1 inhibitor curcumin effectively inhibited cytokine gene expression at the mRNA and the protein level and inhibited activation of NF- κ B in the gingival tissues although the inhibitor did not prevent alveolar bone resorption (Ref. 198). It was also recently reported that aminothiazoles targeting mPGES-1 decrease PGE₂ synthesis in vitro and ameliorate experimental periodontitis in vivo (Ref. 199). PGE₂ inhibitors, targeting the enzyme COX using NSAIDs or specific COX-2 inhibitors, have been shown to block periodontal PGE₂ synthesis and prevent disease progression in numerous animal models and a few clinical studies (Refs 183, 200). Well-designed, large-scale clinical trials are needed to further evaluate the role of PGE₂ inhibitory drugs as new therapeutic strategies in the management of periodontal disease.

Inhibition of proinflammatory cytokines

Cytokines have been validated as therapeutic targets for treatment of numerous inflammatory diseases such as RA, inflammatory bowel disease (IBD) and periodontitis. TNF α was the first cytokine to be validated as a therapeutic target for RA, and although several other cytokine antagonists including TNF α , IL-1 and IL-6 have been or are being validated as biological therapies for treatment of RA, TNF α seems to be the preferred target of first-line biological therapy (Ref. 201). Soluble antagonists to IL-1 and TNF α , at this time only demonstrated in experimental periodontitis, have shown a reduction in loss of connective tissue attachment, osteoclast formation and loss

of alveolar bone (Refs 15, 87, 93). However, although a few studies have reported a reduction of alveolar bone loss in patients with RA in response to anti-TNF α treatment, there are limited results suggesting that anti-TNF α agents can reduce local production of inflammatory cytokines and periodontal inflammation in RA patients with periodontitis (Ref. 202).

Levels of inflammatory cytokines and other mediators can also be regulated through inhibition of intracellular signalling pathways. Induction of cytokines in response to activation of TLRs by bacterial pathogens involves numerous signal transduction pathways including NF- κ B, MAPK and janus kinase-signal transducer and activator of transcription (JAK-STAT). The MAPK signal pathway comprises of the subfamilies extracellular regulated kinases (ERKs) and the c-Jun N-terminal activated kinases (JNK) and p38. Inhibitors that target JNK have been suggested to have therapeutic potential in the chronic inflammatory conditions RA and IBD (Refs 203, 204). Recently, it was reported that silencing the MAP kinase-activated protein kinase-2 (MAPKAPK-2) impeded LPS-induced inflammatory bone loss, decreased the inflammatory infiltrate and reduced osteoclastogenesis (Ref. 205). Moreover, studies on experimental rat periodontitis suggest that orally active p38 MAPK inhibitors can reduce LPS-induced inflammatory cytokine production and osteoclast formation and protect against LPS-stimulated alveolar bone loss and decreased IL-6, IL-1 β and TNF α expression (Ref. 206). This highlights the importance of p38 MAPK signalling in immune cytokine production and periodontal disease progression (Ref. 207).

Cytokine expression is also endogenously regulated through post-transcriptional modulations that affect mRNA stability, known to play an important role in inflammatory disease progression. Cytokines such as TNF α , IL-6 and IL-8, which activate multiple signalling cascades including ERK, JNK, NF- κ B and p38 MAPK are regulated via mRNA stability. The absence of post-transcriptional regulation of the mRNAs of these cytokines may increase cytokine production, leading to tissue destruction (Ref. 208). Thus, RNA-binding proteins and microRNAs, which bind to the AU-rich elements of cytokine mRNA that affect mRNA stability, have been suggested as

potential new treatments for controlling the cytokine mRNA expression (Ref. 208).

Research in progress and conclusions

Continuing advancement in scientific methodology, including high throughput analysis techniques, is enabling studies on genomic variations and gene expression patterns in periodontal disease. Whole-genome microarrays and RNA sequencing will be valuable tools for identifying genetic and biological markers of increased susceptibility to periodontal disease. In recent years, both transcriptome studies and a genome-wide association study have been performed on periodontitis cohorts (Refs 209, 210, 211, 212). The massive amounts of data generated by such studies require painstaking analyses to yield biologically significant results, but the capacity for identification of novel mediators involved in the pathogenesis of periodontitis is promising, especially in sequencing approaches that are unhampered by predefined probe sets (Refs 213, 214). However, upcoming breakthroughs in the understanding and treatment of periodontitis need not be derived only from periodontitis-focused research. Much is to be gained from research progress in other chronic inflammatory conditions. Studies are ongoing to evaluate the role of other proinflammatory cytokines in the pathophysiology of conditions similar to periodontitis, such as RA, Crohn's disease and IBD, and to develop antibodies which specifically target these cytokines for novel future treatment strategies. IL-21, a new member of the type 1 cytokine superfamily, promotes osteoclastogenesis in RA (Ref. 215) and has been suggested as target for immune-mediated diseases, especially for preventing bone destruction (Ref. 216). IL-23, a member of the IL-12 family, has been reported to be involved in osteoclastogenesis via induction of RANKL expression. Treatment with the IL-12p40 monoclonal antibody Ustekinumab against the common p40 subunit of IL-12 and IL-23, which thereby neutralises IL-12 and IL-23, has shown clinical efficacy in patients with Crohn's disease (Ref. 217) and psoriatic arthritis (Ref. 218). Currently, numerous IL-23 receptor antagonists are reported to be under development in clinical or preclinical studies (Refs 219, 220).

As discussed throughout this review, research into the molecular pathogenesis of periodontitis

is continuously producing novel and significant results. Despite extensive research, however, the detailed mechanisms of the pathogenesis of periodontitis are still not elucidated. Nevertheless, the field is moving forward, utilising technological advances and synergy effects from findings in closely related diseases. Periodontitis is currently being connected to the pathogenesis of various systemic diseases and conditions, further emphasising the importance of a deeper understanding of this common condition. Progress in the understanding of periodontal disease may enable adjunctive treatments focused on modulating the host response. Successful novel treatment strategies have the potential to improve both the oral and the systemic health of patients afflicted with periodontitis.

Acknowledgements and funding

Research on the pathogenesis of periodontal disease and molecular periodontology is supported by the Swedish Research Council; the Swedish Patent Revenue Fund; the Swedish Dental Society; Stockholm County Council; and Karolinska Institutet. We thank the peer reviewers for their valuable comments and suggestions on the manuscript.

References

- 1 Burt, B. (2005) Position paper: epidemiology of periodontal diseases. *Journal of Periodontology* 76, 1406-1419
- 2 Papapanou, P.N. (1999) Epidemiology of periodontal diseases: an update. *Journal of the International Academy of Periodontology* 1, 110-116
- 3 Eke, P.I. et al. (2012) Prevalence of periodontitis in adults in the United States: 2009 and 2010. *Journal of Dental Research* 91, 914-920
- 4 Papapanou, P.N. (2012) The prevalence of periodontitis in the US: forget what you were told. *Journal of Dental Research* 91, 907-908
- 5 Savage, A. et al. (2009) A systematic review of definitions of periodontitis and methods that have been used to identify this disease. *Journal of Clinical Periodontology* 36, 458-467
- 6 Tezal, M. and Uribe, S. (2011) A lack of consensus in the measurement methods for and definition of periodontitis. *J Am Dent Assoc* 142, 666-667
- 7 Page, R.C. and Kornman, K.S. (1997) The pathogenesis of human periodontitis: an introduction. *Periodontology* 2000 14, 9-11

- 8 Darveau, R.P. (2010) Periodontitis: a polymicrobial disruption of host homeostasis. *Nature Reviews Microbiology* 8, 481-490
- 9 Birkedal-Hansen, H. (1993) Role of cytokines and inflammatory mediators in tissue destruction. *Journal of Periodontal Research* 28, 500-510
- 10 Hernandez, M. et al. (2011) Host-pathogen interactions in progressive chronic periodontitis. *Journal of Dental Research* 90, 1164-1170
- 11 Phipps, R.P., Borrello, M.A. and Blieden, T.M. (1997) Fibroblast heterogeneity in the periodontium and other tissues. *Journal of Periodontal Research* 32, 159-165
- 12 Graves, D. (2008) Cytokines that promote periodontal tissue destruction. *Journal of Periodontology* 79, 1585-1591
- 13 Bage, T. et al. (2011) Expression of prostaglandin E synthases in periodontitis immunolocalization and cellular regulation. *American Journal of Pathology* 178, 1676-1688
- 14 Assuma, R. et al. (1998) IL-1 and TNF antagonists inhibit the inflammatory response and bone loss in experimental periodontitis. *Journal of Immunology* 160, 403-409
- 15 Delima, A.J. et al. (2002) Inflammation and tissue loss caused by periodontal pathogens is reduced by interleukin-1 antagonists. *Journal of Infectious Diseases* 186, 511-516
- 16 Reddy, M.S. et al. (1993) Efficacy of meclufenamate sodium (Meclomen) in the treatment of rapidly progressive periodontitis. *Journal of Clinical Periodontology* 20, 635-640
- 17 Silva, T.A. et al. (2007) Chemokines in oral inflammatory diseases: apical periodontitis and periodontal disease. *Journal of Dental Research* 86, 306-319
- 18 Bartold, P.M., Cantley, M.D. and Haynes, D.R. (2010) Mechanisms and control of pathologic bone loss in periodontitis. *Periodontology* 2000 53, 55-69
- 19 Tanabe, N. et al. (2005) IL-1 alpha stimulates the formation of osteoclast-like cells by increasing M-CSF and PGE2 production and decreasing OPG production by osteoblasts. *Life Sciences* 77, 615-626
- 20 Bascones, A. et al. (2005) Tissue destruction in periodontitis: bacteria or cytokines fault? *Quintessence International* 36, 299-306
- 21 Page, R.C. et al. (1997) Advances in the pathogenesis of periodontitis: summary of developments, clinical implications and future directions. *Periodontology* 2000 14, 216-248
- 22 Pihlstrom, B.L., Michalowicz, B.S. and Johnson, N.W. (2005) Periodontal diseases. *Lancet* 366, 1809-1820
- 23 Lindhe, J., Hamp, S. and Loe, H. (1973) Experimental periodontitis in the beagle dog. *Journal of Periodontal Research* 8, 1-10
- 24 Loe, H., Theilade, E. and Jensen, S.B. (1965) Experimental gingivitis in man. *Journal of Periodontology* 36, 177-187
- 25 Kornman, K.S. (2008) Mapping the pathogenesis of periodontitis: a new look. *Journal of Periodontology* 79, 1560-1568
- 26 Page, R.C. and Schroeder, H.E. (1976) Pathogenesis of inflammatory periodontal disease: a summary of current work. *Laboratory Investigation* 34, 235-249
- 27 Ranney, R.R. (1991) Immunologic mechanisms of pathogenesis in periodontal diseases: an assessment. *Journal of Periodontal Research* 26, 243-254
- 28 Seymour, G.J. (1987) Possible mechanisms involved in the immunoregulation of chronic inflammatory periodontal disease. *Journal of Dental Research* 66, 2-9
- 29 Corey, L.A. et al. (1993) Self-reported periodontal disease in a Virginia twin population. *Journal of Periodontology* 64, 1205-1208
- 30 Michalowicz, B.S. et al. (2000) Evidence of a substantial genetic basis for risk of adult periodontitis. *Journal of Periodontology* 71, 1699-1707
- 31 Kornman, K.S., Page, R.C. and Tonetti, M.S. (1997) The host response to the microbial challenge in periodontitis: assembling the players. *Periodontology* 2000 14, 33-53
- 32 Madianos, P.N., Bobetsis, Y.A. and Kinane, D.F. (2005) Generation of inflammatory stimuli: how bacteria set up inflammatory responses in the gingiva. *Journal of Clinical Periodontology* 32(Suppl 6), 57-71
- 33 Bartold, P.M. and Narayanan, A.S. (2006) Molecular and cell biology of healthy and diseased periodontal tissues. *Periodontology* 2000 40, 29-49
- 34 Ohlrich, E.J., Cullinan, M.P. and Seymour, G.J. (2009) The immunopathogenesis of periodontal disease. *Australian Dental Journal* 54(Suppl 1), S2-S10
- 35 Kramer, J.M. and Gaffen, S.L. (2007) Interleukin-17: a new paradigm in inflammation, autoimmunity, and therapy. *Journal of Periodontology* 78, 1083-1093
- 36 Garlet, G.P. (2010) Destructive and protective roles of cytokines in periodontitis: a re-appraisal from host defense and tissue destruction viewpoints. *Journal of Dental Research* 89, 1349-1363

- 37 Van Dyke, T.E. and van Winkelhoff, A.J. (2013) Infection and inflammatory mechanisms. *Journal of Clinical Periodontology* 40(Suppl 14), S1-S7
- 38 Darveau, R.P. (2010) Periodontitis: a polymicrobial disruption of host homeostasis. *Nature Reviews Microbiology* 8, 481-490
- 39 Holt, S.C. and Ebersole, J.L. (2005) *Porphyromonas gingivalis*, *Treponema denticola*, and *Tannerella forsythia*: the "red complex", a prototype polybacterial pathogenic consortium in periodontitis. *Periodontology 2000* 38, 72-122
- 40 Mahanonda, R. and Pichyangkul, S. (2007) Toll-like receptors and their role in periodontal health and disease. *Periodontology 2000* 43, 41-55
- 41 Van Dyke, T.E. and Serhan, C.N. (2003) Resolution of inflammation: a new paradigm for the pathogenesis of periodontal diseases. *Journal of Dental Research* 82, 82-90
- 42 Serhan, C.N., Chiang, N. and Van Dyke, T.E. (2008) Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. *Nature Reviews Immunology* 8, 349-361
- 43 Nistala, K. and Wedderburn, L.R. (2009) Th17 and regulatory T cells: rebalancing pro- and anti-inflammatory forces in autoimmune arthritis. *Rheumatology (Oxford)* 48, 602-606
- 44 Andre, S. et al. (2009) Surveillance of antigen-presenting cells by CD4+ CD25+ regulatory T cells in autoimmunity: immunopathogenesis and therapeutic implications. *American Journal of Pathology* 174, 1575-1587
- 45 Okui, T. et al. (2012) The presence of IL-17 + /FOXP3+ double-positive cells in periodontitis. *Journal of Dental Research* 91, 574-579
- 46 Flavell, S.J. et al. (2008) Fibroblasts as novel therapeutic targets in chronic inflammation. *British Journal of Pharmacology* 153, S241-S246
- 47 Heath, J.K. et al. (1987) Bacterial antigens induce collagenase and prostaglandin E2 synthesis in human gingival fibroblasts through a primary effect on circulating mononuclear cells. *Infection and Immunity* 55, 2148-2154
- 48 Meikle, M.C. et al. (1994) Immunolocalization of matrix metalloproteinases and TIMP-1 (tissue inhibitor of metalloproteinases) in human gingival tissues from periodontitis patients. *Journal of Periodontal Research* 29, 118-126
- 49 Reynolds, J.J. and Meikle, M.C. (1997) Mechanisms of connective tissue matrix destruction in periodontitis. *Periodontology 2000* 14, 144-157
- 50 Bage, T. et al. (2010) Signal pathways JNK and NF-kappaB, identified by global gene expression profiling, are involved in regulation of TNFalpha-induced mPGES-1 and COX-2 expression in gingival fibroblasts. *BMC Genomics* 11, 241-200
- 51 Domeij, H., Modeer, T. and Yucel-Lindberg, T. (2004) Matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 production in human gingival fibroblasts: the role of protein kinase C. *Journal of Periodontal Research* 39, 308-314
- 52 Nishikawa, M. et al. (2002) Effects of TNFalpha and prostaglandin E2 on the expression of MMPs in human periodontal ligament fibroblasts. *Journal of Periodontal Research* 37, 167-176
- 53 Noguchi, K., Shitashige, M. and Ishikawa, I. (1999) Involvement of cyclooxygenase-2 in interleukin-1alpha-induced prostaglandin production by human periodontal ligament cells. *Journal of Periodontology* 70, 902-908
- 54 Hormdee, D. et al. (2005) Protein kinase-A-dependent osteoprotegerin production on interleukin-1 stimulation in human gingival fibroblasts is distinct from periodontal ligament fibroblasts. *Clinical and Experimental Immunology* 142, 490-497
- 55 Holmlund, A., Hanstrom, L. and Lerner, U.H. (2004) Bone resorbing activity and cytokine levels in gingival crevicular fluid before and after treatment of periodontal disease. *Journal of Clinical Periodontology* 31, 475-482
- 56 Thunell, D.H. et al. (2010) A multiplex immunoassay demonstrates reductions in gingival crevicular fluid cytokines following initial periodontal therapy. *Journal of Periodontal Research* 45, 148-152
- 57 Tymkiw, K.D. et al. (2011) Influence of smoking on gingival crevicular fluid cytokines in severe chronic periodontitis. *Journal of Clinical Periodontology* 38, 219-228
- 58 Ishihara, Y. et al. (1997) Gingival crevicular interleukin-1 and interleukin-1 receptor antagonist levels in periodontally healthy and diseased sites. *Journal of Periodontal Research* 32, 524-529
- 59 Gamonal, J. et al. (2000) Levels of interleukin-1 beta, -8, and -10 and RANTES in gingival crevicular fluid and cell populations in adult periodontitis patients and the effect of periodontal treatment. *Journal of Periodontology* 71, 1535-1545
- 60 Rescala, B. et al. (2010) Immunologic and microbiologic profiles of chronic and aggressive periodontitis subjects. *Journal of Periodontology* 81, 1308-1316
- 61 Giannopoulou, C., Kamma, J.J. and Mombelli, A. (2003) Effect of inflammation, smoking and stress

- on gingival crevicular fluid cytokine level. *Journal of Clinical Periodontology* 30, 145-153
- 62 Ertugrul, A.S. et al. (2013) Comparison of CCL28, interleukin-8, interleukin-1beta and tumor necrosis factor-alpha in subjects with gingivitis, chronic periodontitis and generalized aggressive periodontitis. *Journal of Periodontal Research* 48, 44-51
- 63 Fujita, Y. et al. (2012) Correlations between pentraxin 3 or cytokine levels in gingival crevicular fluid and clinical parameters of chronic periodontitis. *Odontology* 100, 215-221
- 64 Cetinkaya, B. et al. (2013) Proinflammatory and anti-inflammatory cytokines in gingival crevicular fluid and serum of patients with rheumatoid arthritis and patients with chronic periodontitis. *Journal of Periodontology* 84, 84-93
- 65 Lo, Y.J. et al. (1999) Interleukin 1beta-secreting cells in inflamed gingival tissue of adult periodontitis patients. *Cytokine* 11, 626-633
- 66 Hou, L.T. et al. (2003) Interleukin-1beta, clinical parameters and matched cellular-histopathologic changes of biopsied gingival tissue from periodontitis patients. *Journal of Periodontal Research* 38, 247-254
- 67 Calderin, S., Garcia-Nunez, J.A. and Gomez, C. (2013) Short-term clinical and osteoimmunological effects of scaling and root planing complemented by simple or repeated laser phototherapy in chronic periodontitis. *Lasers in Medical Science* 28, 157-166
- 68 Pradeep, A.R., Roopa, Y. and Swati, P.P. (2008) Interleukin-4, a T-helper 2 cell cytokine, is associated with the remission of periodontal disease. *Journal of Periodontal Research* 43, 712-716
- 69 Tsai, C.C. et al. (2007) Changes in gingival crevicular fluid interleukin-4 and interferon-gamma in patients with chronic periodontitis before and after periodontal initial therapy. *Kaohsiung Journal of Medical Sciences* 23, 1-7
- 70 Zhao, L. et al. (2011) Effect of non-surgical periodontal therapy on the levels of Th17/Th1/Th2 cytokines and their transcription factors in Chinese chronic periodontitis patients. *Journal of Clinical Periodontology* 38, 509-516
- 71 Kurtis, B. et al. (1999) IL-6 levels in gingival crevicular fluid (GCF) from patients with non-insulin dependent diabetes mellitus (NIDDM), adult periodontitis and healthy subjects. *Journal of Oral Sciences* 41, 163-167
- 72 Gamonal, J. et al. (2001) Characterization of cellular infiltrate, detection of chemokine receptor CCR5 and interleukin-8 and RANTES chemokines in adult periodontitis. *Journal of Periodontal Research* 36, 194-203
- 73 Sanchez-Hernandez, P.E., et al. (2011) IL-12 and IL-18 levels in serum and gingival tissue in aggressive and chronic periodontitis. *Oral Diseases* 17, 522-529
- 74 Honda, T. et al. (2008) Elevated expression of IL-17 and IL-12 genes in chronic inflammatory periodontal disease. *Clinica Chimica Acta* 395, 137-141
- 75 Vernal, R. et al. (2005) Levels of interleukin-17 in gingival crevicular fluid and in supernatants of cellular cultures of gingival tissue from patients with chronic periodontitis. *Journal of Clinical Periodontology* 32, 383-389
- 76 Pradeep, A.R. et al. (2009) Correlation of gingival crevicular fluid interleukin-18 and monocyte chemoattractant protein-1 levels in periodontal health and disease. *Journal of Periodontology* 80, 1454-1461
- 77 Dutzan, N. et al. (2011) Levels of interleukin-21 in patients with untreated chronic periodontitis. *Journal of Periodontology* 82, 1483-1489
- 78 Dutzan, N. et al. (2009) Levels of interferon-gamma and transcription factor T-bet in progressive periodontal lesions in patients with chronic periodontitis. *Journal of Periodontology* 80, 290-296
- 79 Kurtis, B. et al. (2005) Gingival crevicular fluid levels of monocyte chemoattractant protein-1 and tumor necrosis factor-alpha in patients with chronic and aggressive periodontitis. *Journal of Periodontology* 76, 1849-1855
- 80 Tervahartiala, T. et al. (2001) Tumor necrosis factor-alpha and its receptors, p55 and p75, in gingiva of adult periodontitis. *Journal of Dental Research* 80, 1535-1539
- 81 de Lima Oliveira, A.P. et al. (2012) Effects of periodontal therapy on GCF cytokines in generalized aggressive periodontitis subjects. *Journal of Clinical Periodontology* 39, 295-302
- 82 de Oliveira, R.R. et al. (2009) Antimicrobial photodynamic therapy in the non-surgical treatment of aggressive periodontitis: cytokine profile in gingival crevicular fluid, preliminary results. *Journal of Periodontology* 80, 98-105
- 83 Garlet, G.P. et al. (2003) Patterns of chemokines and chemokine receptors expression in different forms of human periodontal disease. *Journal of Periodontal Research* 38, 210-217
- 84 Deo, V. and Bhongade, M.L. (2010) Pathogenesis of periodontitis: role of cytokines in host response. *Dentistry Today* 29, 60-62, 64-6; quiz 68-9
- 85 Prabhu, A., Michalowicz, B.S. and Mathur, A. (1996) Detection of local and systemic cytokines in adult periodontitis. *Journal of Periodontology* 67, 515-522

- 86 Marcaccini, A.M. et al. (2009) Circulating interleukin-6 and high-sensitivity C-reactive protein decrease after periodontal therapy in otherwise healthy subjects. *Journal of Periodontology* 80, 594-602
- 87 Graves, D.T. and Cochran, D. (2003) The contribution of interleukin-1 and tumor necrosis factor to periodontal tissue destruction. *Journal of Periodontology* 74, 391-401
- 88 Perozini, C. et al. (2010) Gingival crevicular fluid biochemical markers in periodontal disease: a cross-sectional study. *Quintessence International* 41, 877-883
- 89 Stashenko, P. et al. (1991) Tissue levels of bone resorptive cytokines in periodontal disease. *Journal of Periodontology* 62, 504-509
- 90 Gaspersic, R. et al. (2003) Influence of subcutaneous administration of recombinant TNF-alpha on ligature-induced periodontitis in rats. *Journal of Periodontal Research* 38, 198-203
- 91 Pers, J.O. et al. (2008) Anti-TNF-alpha immunotherapy is associated with increased gingival inflammation without clinical attachment loss in subjects with rheumatoid arthritis. *Journal of Periodontology* 79, 1645-1651
- 92 Koide, M. et al. (1995) In vivo administration of IL-1 beta accelerates silk ligature-induced alveolar bone resorption in rats. *Journal of Oral Pathology and Medicine* 24, 420-434
- 93 Delima, A.J. et al. (2001) Soluble antagonists to interleukin-1 (IL-1) and tumor necrosis factor (TNF) inhibits loss of tissue attachment in experimental periodontitis. *Journal of Clinical Periodontology* 28, 233-240
- 94 Weber, A., Wasiliew, P. and Kracht, M. (2010) Interleukin-1 (IL-1) pathway. *Sci Signalling* 3, cm1
- 95 Kwan Tat, S. et al. (2004) IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology. *Cytokine and Growth Factor Reviews* 15, 49-60
- 96 Yucel-Lindberg, T., Nilsson, S. and Modeer, T. (1999) Signal transduction pathways involved in the synergistic stimulation of prostaglandin production by interleukin-1beta and tumor necrosis factor alpha in human gingival fibroblasts. *Journal of Dental Research* 78, 61-68
- 97 Huang, G.T., Haake, S.K. and Park, N.H. (1998) Gingival epithelial cells increase interleukin-8 secretion in response to *Actinobacillus actinomycetemcomitans* challenge. *Journal of Periodontology* 69, 1105-1110
- 98 Liu, R.K. et al. (2001) Polymorphonuclear neutrophils and their mediators in gingival tissues from generalized aggressive periodontitis. *Journal of Periodontology* 72, 1545-1553
- 99 Preshaw, P.M. and Taylor, J.J. How has research into cytokine interactions and their role in driving immune responses impacted our understanding of periodontitis? *Journal of Clinical Periodontology* 38(Suppl 11), 60-84
- 100 Nikolopoulos, G.K. et al. (2008) Cytokine gene polymorphisms in periodontal disease: a meta-analysis of 53 studies including 4178 cases and 4590 controls. *Journal of Clinical Periodontology* 35, 754-767
- 101 Zhang, J. et al. (2011) Gene polymorphisms and periodontitis. *Periodontology 2000* 56, 102-124
- 102 McDevitt, M.J. et al. (2000) Interleukin-1 genetic association with periodontitis in clinical practice. *Journal of Periodontology* 71, 156-163
- 103 Galbraith, G.M. et al. (1999) Polymorphic cytokine genotypes as markers of disease severity in adult periodontitis. *Journal of Clinical Periodontology* 26, 705-709
- 104 Brett, P.M. et al. (2005) Functional gene polymorphisms in aggressive and chronic periodontitis. *Journal of Dental Research* 84, 1149-1153
- 105 Zhong, Q. et al. (2012) Interleukin-10 gene polymorphisms and chronic/aggressive periodontitis susceptibility: a meta-analysis based on 14 case-control studies. *Cytokine* 60, 47-54
- 106 Fassmann, A. et al. (2003) Polymorphisms in the +252(A/G) lymphotoxin-alpha and the -308(A/G) tumor necrosis factor-alpha genes and susceptibility to chronic periodontitis in a Czech population. *Journal of Periodontal Research* 38, 394-399
- 107 Peters-Golden, M. and Henderson, W.R., Jr (2007) Leukotrienes. *New England Journal of Medicine* 357, 1841-1854
- 108 Hikiji, H. et al. (2008) The roles of prostanoids, leukotrienes, and platelet-activating factor in bone metabolism and disease. *Progress in Lipid Research* 47, 107-126
- 109 Pradeep, A.R. et al. (2007) Gingival crevicular fluid levels of leukotriene B4 in periodontal health and disease. *Journal of Periodontology* 78, 2325-2330
- 110 Back, M. et al. (2007) Increased leukotriene concentrations in gingival crevicular fluid from subjects with periodontal disease and atherosclerosis. *Atherosclerosis* 193, 389-394
- 111 Hasturk, H. et al. (2006) RvE1 protects from local inflammation and osteoclast-mediated bone destruction in periodontitis. *FASEB Journal* 20, 401-403

- 112 Herrera, B.S. et al. (2008) An endogenous regulator of inflammation, resolvin E1, modulates osteoclast differentiation and bone resorption. *British Journal of Pharmacology* 155, 1214-1223
- 113 Fredman, G., et al. Impaired phagocytosis in localized aggressive periodontitis: rescue by Resolvin E1. *PLoS ONE* 6, e24422
- 114 Wan, M. et al. (2011) Leukotriene B4/antimicrobial peptide LL-37 proinflammatory circuits are mediated by BLT1 and FPR2/ALX and are counterregulated by lipoxin A4 and resolvin E1. *FASEB Journal* 25, 1697-1705
- 115 Funk, C.D. (2001) Prostaglandins and leukotrienes: advances in eicosanoid biology. *Science* 294, 1871-1875
- 116 Harris, S.G. et al. (2002) Prostaglandins as modulators of immunity. *Trends in Immunology* 23, 144-150
- 117 Bergstrom, S. (1967) Prostaglandins: members of a new hormonal system. These physiologically very potent compounds of ubiquitous occurrence are formed from essential fatty acids. *Science* 157, 382-391
- 118 Samuelsson, B. et al. (1975) Prostaglandins. *Annual Review of Biochemistry* 44, 669-695
- 119 Granstrom, E. (1984) The arachidonic acid cascade. The prostaglandins, thromboxanes and leukotrienes. *Inflammation* 8(Suppl), S15-S25
- 120 Noguchi, K. and Ishikawa, I. (2007) The roles of cyclooxygenase-2 and prostaglandin E2 in periodontal disease. *Periodontology* 2000 43, 85-101
- 121 Kaneko, H. et al. (2007) Effects of prostaglandin E2 and lipopolysaccharide on osteoclastogenesis in RAW 264.7 cells. *Prostaglandins Leukot Essent Fatty Acids* 77, 181-186
- 122 Raisz, L.G. (1990) The role of prostaglandins in the local regulation of bone metabolism. *Progress in Clinical and Biological Research* 332, 195-203
- 123 Blackwell, K.A., Raisz, L.G. and Pilbeam, C.C. (2010) Prostaglandins in bone: bad cop, good cop? *Trends in Endocrinology and Metabolism* 21, 294-301
- 124 Suzawa, T. et al. (2000) The role of prostaglandin E receptor subtypes (EP1, EP2, EP3, and EP4) in bone resorption: an analysis using specific agonists for the respective EPs. *Endocrinology* 141, 1554-1559
- 125 Miyaura, C. et al. (2000) Impaired bone resorption to prostaglandin E2 in prostaglandin E receptor EP4-knockout mice. *Journal of Biological Chemistry* 275, 19819-19823
- 126 ElAttar, T.M. (1976) Prostaglandin E2 in human gingiva in health and disease and its stimulation by female sex steroids. *Prostaglandins* 11, 331-341
- 127 Eberhard, J. et al. (2000) Quantitation of arachidonic acid metabolites in small tissue biopsies by reversed-phase high-performance liquid chromatography. *Analytical Biochemistry* 280, 258-263
- 128 Vardar, S., Baylas, H. and Huseyinov, A. (2003) Effects of selective cyclooxygenase-2 inhibition on gingival tissue levels of prostaglandin E2 and prostaglandin F2alpha and clinical parameters of chronic periodontitis. *Journal of Periodontology* 74, 57-63
- 129 Offenbacher, S., Heasman, P.A. and Collins, J.G. (1993) Modulation of host PGE2 secretion as a determinant of periodontal disease expression. *Journal of Periodontology* 64, 432-444
- 130 Preshaw, P.M. and Heasman, P.A. (2002) Prostaglandin E2 concentrations in gingival crevicular fluid: observations in untreated chronic periodontitis. *Journal of Clinical Periodontology* 29, 15-20
- 131 Offenbacher, S., Odle, B.M. and Van Dyke, T.E. (1986) The use of crevicular fluid prostaglandin E2 levels as a predictor of periodontal attachment loss. *Journal of Periodontal Research* 21, 101-112
- 132 Champagne, C.M. et al. (2003) Potential for gingival crevice fluid measures as predictors of risk for periodontal diseases. *Periodontology* 2000 31, 167-180
- 133 Schaefer, A.S. et al. (2010) COX-2 is associated with periodontitis in Europeans. *Journal of Dental Research* 89, 384-388
- 134 Zhang, S. et al. (2010) Alteration of PTGS2 promoter methylation in chronic periodontitis. *Journal of Dental Research* 89, 133-137
- 135 Nichols, F. and Maraj, B. (1998) Relationship between hydroxy fatty acids and prostaglandin E2 in gingival tissue. *Infection and Immunity* 66, 5805-5811
- 136 Potempa, J., Banbula, A. and Travis, J. (2000) Role of bacterial proteinases in matrix destruction and modulation of host responses. *Periodontology* 2000 24, 153-192
- 137 Laugisch, O. et al. (2012) Periodontal pathogens affect the level of protease inhibitors in gingival crevicular fluid. *Molecular Oral Microbiology* 27, 45-56
- 138 Sorsa, T. et al. (2006) Matrix metalloproteinases: contribution to pathogenesis, diagnosis and treatment of periodontal inflammation. *Annals of Medicine* 38, 306-321
- 139 McMillan, S.J. et al. (2004) Matrix metalloproteinase-9 deficiency results in enhanced allergen-induced airway inflammation. *Journal of Immunology* 172, 2586-2594

- 140 Owen, C.A. et al. (2004) Membrane-bound matrix metalloproteinase-8 on activated polymorphonuclear cells is a potent, tissue inhibitor of metalloproteinase-resistant collagenase and serpinase. *Journal of Immunology* 172, 7791-7803
- 141 Uitto, V.J., Overall, C.M. and McCulloch, C. (2003) Proteolytic host cell enzymes in gingival crevice fluid. *Periodontology* 2000 31, 77-104
- 142 Sorsa, T., Tjaderhane, L. and Salo, T. (2004) Matrix metalloproteinases (MMPs) in oral diseases. *Oral Diseases* 10, 311-318
- 143 Gursoy, U.K. et al. (2010) Salivary MMP-8, TIMP-1, and ICTP as markers of advanced periodontitis. *Journal of Clinical Periodontology* 37, 487-493
- 144 Letra, A. et al. (2012) MMP3 and TIMP1 variants contribute to chronic periodontitis and may be implicated in disease progression. *Journal of Clinical Periodontology* 39, 707-716
- 145 Li, G. et al. (2012) Association of matrix metalloproteinase (MMP)-1, 3, 9, interleukin (IL)-2, 8 and cyclooxygenase (COX)-2 gene polymorphisms with chronic periodontitis in a Chinese population. *Cytokine* 60, 552-560
- 146 Domeij, H., Yucel-Lindberg, T. and Modeer, T. (2002) Signal pathways involved in the production of MMP-1 and MMP-3 in human gingival fibroblasts. *European Journal of Oral Sciences* 110, 302-306
- 147 Domeij, H. et al. (2005) Cell expression of MMP-1 and TIMP-1 in co-cultures of human gingival fibroblasts and monocytes: the involvement of ICAM-1. *Biochemical and Biophysical Research Communications* 338, 1825-1833
- 148 Abe, M. et al. (2001) Induction of collagenase-2 (matrix metalloproteinase-8) gene expression by interleukin-1beta in human gingival fibroblasts. *Journal of Periodontal Research* 36, 153-159
- 149 Kuo, P.J. et al. (2012) Cyclosporine-A inhibits MMP-2 and -9 activities in the presence of *Porphyromonas gingivalis* lipopolysaccharide: an experiment in human gingival fibroblast and U937 macrophage co-culture. *Journal of Periodontal Research* 47, 431-438
- 150 Zhang, W., Song, F. and Windsor, L.J. (2010) Effects of tobacco and *P. gingivalis* on gingival fibroblasts. *Journal of Dental Research* 89, 527-531
- 151 Choi, Y.A. et al. (2004) Interleukin-1beta stimulates matrix metalloproteinase-2 expression via a prostaglandin E2-dependent mechanism in human chondrocytes. *Experimental and Molecular Medicine* 36, 226-232
- 152 Khan, K.M. et al. (2012) Matrix metalloproteinase-dependent microsomal prostaglandin E synthase-1 expression in macrophages: role of TNF-alpha and the EP4 prostanoid receptor. *Journal of Immunology* 188, 1970-1980
- 153 Gosset, M. et al. (2010) Inhibition of matrix metalloproteinase-3 and -13 synthesis induced by IL-1beta in chondrocytes from mice lacking microsomal prostaglandin E synthase-1. *Journal of Immunology* 185, 6244-6252
- 154 Kida, Y. et al. (2005) Interleukin-1 stimulates cytokines, prostaglandin E2 and matrix metalloproteinase-1 production via activation of MAPK/AP-1 and NF-kappaB in human gingival fibroblasts. *Cytokine* 29, 159-168
- 155 Kim, C.H. et al. (2005) PGE2 induces the gene expression of bone matrix metalloproteinase-1 in mouse osteoblasts by cAMP-PKA signaling pathway. *International Journal of Biochemistry and Cell Biology* 37, 375-385
- 156 Verstappen, J. and Von den Hoff, J.W. (2006) Tissue inhibitors of metalloproteinases (TIMPs): their biological functions and involvement in oral disease. *Journal of Dental Research* 85, 1074-1084
- 157 Soell, M., Elkaim, R. and Tenenbaum, H. (2002) Cathepsin C, matrix metalloproteinases, and their tissue inhibitors in gingiva and gingival crevicular fluid from periodontitis-affected patients. *Journal of Dental Research* 81, 174-178
- 158 Golub, L.M. et al. (1998) Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. *Advances in Dental Research* 12, 12-26
- 159 Braun, T. and Zwerina, J. (2011) Positive regulators of osteoclastogenesis and bone resorption in rheumatoid arthritis. *Arthritis Research and Therapy* 13, 235
- 160 Schett, G. (2011) Effects of inflammatory and anti-inflammatory cytokines on the bone. *European Journal of Clinical Investigation* 41, 1361-1366
- 161 Takayanagi, H. (2005) Mechanistic insight into osteoclast differentiation in osteoimmunology. *Journal of Molecular Medicine (Berlin)* 83, 170-179
- 162 Maeda, K. et al. (2012) Wnt5a-Ror2 signaling between osteoblast-lineage cells and osteoclast precursors enhances osteoclastogenesis. *Nature Medicine* 18, 405-412
- 163 Kinane, D.F. et al. (2011) Host-response: understanding the cellular and molecular mechanisms of host-microbial interactions—consensus of the Seventh European Workshop on Periodontology. *Journal of Clinical Periodontology* 38 (Suppl 11), 44-48
- 164 Mogi, M. et al. (2004) Differential expression of RANKL and osteoprotegerin in gingival crevicular

- fluid of patients with periodontitis. *Journal of Dental Research* 83, 166-169
- 165 Pfeilschifter, J. et al. (1989) Interleukin-1 and tumor necrosis factor stimulate the formation of human osteoclastlike cells in vitro. *Journal of Bone Mineral Research* 4, 113-118
- 166 Wei, S. et al. (2005) IL-1 mediates TNF-induced osteoclastogenesis. *Journal of Clinical Investigation* 115, 282-290
- 167 Brechter, A.B. and Lerner, U.H. (2007) Bradykinin potentiates cytokine-induced prostaglandin biosynthesis in osteoblasts by enhanced expression of cyclooxygenase 2, resulting in increased RANKL expression. *Arthritis and Rheumatism* 56, 910-923
- 168 Axmann, R. et al. (2009) Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo. *Arthritis and Rheumatism* 60, 2747-2756
- 169 Jimi, E. et al. (2004) Selective inhibition of NF-kappa B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. *Nature Medicine* 10, 617-624
- 170 Choi, B.K. et al. (2005) Prostaglandin E(2) is a main mediator in receptor activator of nuclear factor-kappaB ligand-dependent osteoclastogenesis induced by *Porphyromonas gingivalis*, *Treponema denticola*, and *Treponema socranskii*. *Journal of Periodontology* 76, 813-820
- 171 Brandstrom, H. et al. (1998) Regulation of osteoprotegerin mRNA levels by prostaglandin E2 in human bone marrow stroma cells. *Biochemical and Biophysical Research Communications* 247, 338-341
- 172 Souza, J.A. et al. (2012) Modulation of host cell signaling pathways as a therapeutic approach in periodontal disease. *Journal of Applied Oral Science* 20, 128-138
- 173 Giannobile, W.V. (2008) Host-response therapeutics for periodontal diseases. *Journal of Periodontology* 79, 1592-1600
- 174 Bingham, C.O. III and Austen, K.F. (1999) Phospholipase A2 enzymes in eicosanoid generation. *Proceedings of the Association of American Physicians* 111, 516-524
- 175 Needleman, P. (1978) Characterization of the reaction sequence involved in phospholipid labeling and deacylation and prostaglandin synthesis and actions. *Journal of Allergy and Clinical Immunology* 62, 96-102
- 176 Smith, W.L. and Song, I. (2002) The enzymology of prostaglandin endoperoxide H synthases-1 and -2. *Prostaglandins and Other Lipid Mediators* 68-69, 115-128
- 177 Smith, W.L., Marnett, L.J. and DeWitt, D.L. (1991) Prostaglandin and thromboxane biosynthesis. *Pharmacology and Therapeutics* 49, 153-179
- 178 Jakobsson, P.J. et al. (1999) Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. *Proceedings of the National Academy of Sciences of the United States of America* 96, 7220-7225
- 179 Watanabe, K. et al. (1997) Two types of microsomal prostaglandin E synthase: glutathione-dependent and -independent prostaglandin E synthases. *Biochemical and Biophysical Research Communications* 235, 148-152
- 180 Vane, J.R. (1971) Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. *Nature New Biology* 231, 232-235
- 181 Rouzer, C.A. and Marnett, L.J. (2009) Cyclooxygenases: structural and functional insights. *Journal of Lipid Research* 50(Suppl), S29-S34
- 182 Fracon, R.N. et al. (2008) Prostaglandins and bone: potential risks and benefits related to the use of nonsteroidal anti-inflammatory drugs in clinical dentistry. *Journal of Oral Science* 50, 247-252
- 183 Salvi, G.E. and Lang, N.P. (2005) The effects of non-steroidal anti-inflammatory drugs (selective and non-selective) on the treatment of periodontal diseases. *Current Pharmaceutical Design* 11, 1757-1769
- 184 Faizuddin, M. et al. (2012) Association between long-term aspirin use and periodontal attachment level in humans: a cross-sectional investigation. *Australian Dental Journal* 57, 45-50
- 185 Buduneli, N. et al. (2010) Clinical findings and gingival crevicular fluid prostaglandin E2 and interleukin-1-beta levels following initial periodontal treatment and short-term meloxicam administration. *Expert Opin on Pharmacotherapy* 11, 1805-1812
- 186 Vardar-Sengul, S. et al. (2008) The effects of selective COX-2 inhibitor/celecoxib and omega-3 fatty acid on matrix metalloproteinases, TIMP-1, and laminin-5gamma2-chain immunolocalization in experimental periodontitis. *Journal of Periodontology* 79, 1934-1941
- 187 Funk, C.D. and FitzGerald, G.A. (2007) COX-2 inhibitors and cardiovascular risk. *Journal of Cardiovascular Pharmacology* 50, 470-479
- 188 Friesen, R.W. and Mancini, J.A. (2008) Microsomal prostaglandin E2 synthase-1 (mPGES-1): a novel anti-inflammatory therapeutic target. *Journal of Medicinal Chemistry* 51, 4059-4067

- 189 Koeberle, A. and Werz, O. (2009) Inhibitors of the microsomal prostaglandin E(2) synthase-1 as alternative to non steroidal anti-inflammatory drugs (NSAIDs)—a critical review. *Current Medicinal Chemistry* 16, 4274-4296
- 190 Giroux, A. et al. (2009) Discovery of disubstituted phenanthrene imidazoles as potent, selective and orally active mPGES-1 inhibitors. *Bioorganic and Medicinal Chemistry Letters* 19, 5837-5841
- 191 Riendeau, D. et al. (2005) Inhibitors of the inducible microsomal prostaglandin E2 synthase (mPGES-1) derived from MK-886. *Bioorganic and Medicinal Chemistry Letters* 15, 3352-3355
- 192 Koeberle, A., Northoff, H. and Werz, O. (2009) Curcumin blocks prostaglandin E2 biosynthesis through direct inhibition of the microsomal prostaglandin E2 synthase-1. *Molecular Cancer Therapeutics* 8, 2348-2355
- 193 Koeberle, A. et al. (2009) Green tea epigallocatechin-3-gallate inhibits microsomal prostaglandin E(2) synthase-1. *Biochemical and Biophysical Research Communications* 388, 350-354
- 194 Xu, D. et al. (2008) MF63 [2-(6-chloro-1H-phenanthro[9,10-d]imidazol-2-yl)-isophthalonitrile], a selective microsomal prostaglandin E synthase-1 inhibitor, relieves pyresis and pain in preclinical models of inflammation. *Journal of Pharmacology and Experimental Therapeutics* 326, 754-763
- 195 Guerrero, M.D. et al. (2009) Anti-inflammatory and analgesic activity of a novel inhibitor of microsomal prostaglandin E synthase-1 expression. *European Journal of Pharmacology* 620, 112-119
- 196 Bruno, A. et al. (2010) Effects of AF3442 [N-(9-ethyl-9H-carbazol-3-yl)-2-(trifluoromethyl)benzamide], a novel inhibitor of human microsomal prostaglandin E synthase-1, on prostanoid biosynthesis in human monocytes in vitro. *Biochem Pharmacol* 79, 974-981
- 197 Mbalaviele, G. et al. (2010) Distinction of microsomal prostaglandin E synthase-1 (mPGES-1) inhibition from cyclooxygenase-2 inhibition in cells using a novel, selective mPGES-1 inhibitor. *Biochemical Pharmacology* 79, 1445-1454
- 198 Guimaraes, M.R. et al. (2011) Potent anti-inflammatory effects of systemically administered curcumin modulate periodontal disease in vivo. *Journal of Periodontal Research* 46, 269-279
- 199 Kats, A. et al. (2013) Inhibition of microsomal prostaglandin E synthase-1 by aminothiazoles decreases prostaglandin E2 synthesis in vitro and ameliorates experimental periodontitis in vivo. *FASEB Journal* 27, 2328-2341
- 200 Yen, C.A. et al. (2008) The effect of a selective cyclooxygenase-2 inhibitor (celecoxib) on chronic periodontitis. *Journal of Periodontology* 79, 104-113
- 201 Taylor, P.C. and Feldmann, M. (2009) Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. *Nature Reviews Rheumatology* 5, 578-582
- 202 Han, J.Y. and Reynolds, M.A. (2012) Effect of anti-rheumatic agents on periodontal parameters and biomarkers of inflammation: a systematic review and meta-analysis. *Journal of Periodontal and Implant Science* 42, 3-12
- 203 Han, Z. et al. (1999) Jun N-terminal kinase in rheumatoid arthritis. *Journal of Pharmacology and Experimental Therapeutics* 291, 124-130
- 204 Mitsuyama, K. et al. (2006) Pro-inflammatory signaling by Jun-N-terminal kinase in inflammatory bowel disease. *International Journal of Molecular Medicine* 17, 449-455
- 205 Li, Q. et al. (2011) Silencing mitogen-activated protein kinase-activated protein kinase-2 arrests inflammatory bone loss. *Journal of Pharmacology and Experimental Therapeutics* 336, 633-642
- 206 Kirkwood, K.L. et al. (2007) A p38alpha selective mitogen-activated protein kinase inhibitor prevents periodontal bone loss. *Journal of Pharmacology and Experimental Therapeutics* 320, 56-63
- 207 Li, Q., Valerio, M.S. and Kirkwood, K.L. (2012) MAPK usage in periodontal disease progression. *Journal of Signal Transduction* 2012, 308943
- 208 Palanisamy, V. et al. (2012) Control of cytokine mRNA expression by RNA-binding proteins and microRNAs. *Journal of Dental Research* 91, 651-658
- 209 Davanian, H. et al. (2012) Gene expression profiles in paired gingival biopsies from periodontitis-affected and healthy tissues revealed by massively parallel sequencing. *PLoS ONE* 7, e46440
- 210 Schaefer, A.S. et al. (2010) A genome-wide association study identifies GLT6D1 as a susceptibility locus for periodontitis. *Human Molecular Genetics* 19, 553-562
- 211 Beikler, T. et al. (2008) Gene expression in periodontal tissues following treatment. *BMC Medical Genomics* 1, 30
- 212 Demmer, R.T. et al. (2008) Transcriptomes in healthy and diseased gingival tissues. *Journal of Periodontology* 79, 2112-2124
- 213 Richard, H. et al. (2010) Prediction of alternative isoforms from exon expression levels in RNA-Seq experiments. *Nucleic Acids Research* 38, e112

- 214 Sultan, M. et al. (2008) A global view of gene activity and alternative splicing by deep sequencing of the human transcriptome. *Science* 321, 956-960
- 215 Kwok, S.K. et al. (2012) Interleukin-21 promotes osteoclastogenesis in humans with rheumatoid arthritis and in mice with collagen-induced arthritis. *Arthritis and Rheumatism* 64, 740-751
- 216 Monteleone, G., Pallone, F. and Macdonald, T.T. (2009) Interleukin-21 as a new therapeutic target for immune-mediated diseases. *Trends in Pharmacological Sciences* 30, 441-447
- 217 Fuss, I.J. et al. (2006) Both IL-12p70 and IL-23 are synthesized during active Crohn's disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody. *Inflammatory Bowel Diseases* 12, 9-15
- 218 Gottlieb, A. et al. (2009) Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. *Lancet* 373, 633-640
- 219 Duvallet, E. et al. (2011) Interleukin-23: a key cytokine in inflammatory diseases. *Annals of Medicine* 43, 503-511
- 220 Tang, C. et al. (2012) Interleukin-23: as a drug target for autoimmune inflammatory diseases. *Immunology* 135, 112-124

Features associated with this article

Figures

Figure 1. Characteristics of periodontitis.

Figure 2. Schematic overview of the pathogenesis of periodontitis.

Figure 3. Inflammatory mediators in the pathogenesis of periodontitis.

Table

Table 1. Cytokine levels in the gingival crevicular fluid and in gingival tissue.

Citation details for this article

Tülay Yucel-Lindberg and Tove Båge (2013) Inflammatory mediators in the pathogenesis of periodontitis. *Expert Rev. Mol. Med.* Vol. 15, e7, August 2013, doi:10.1017/erm.2013.8